Results 171 to 180 of about 577,308 (213)

Insights into JAK2-V617F mutation in CML

The Lancet Oncology, 2007
a case of JAK2-V617F mutation is CML.
Monica Bocchia, VANNUCCHI, ALESSANDRO MARIA, Alessandro Gozzetti, GUGLIELMELLI, PAOLA, POLI, GIADA, Rosaria Crupi, Marzia Defina, BOSI, ALBERTO, Lauria Francesco   +8 more
openaire   +5 more sources

The V617F JAK2 mutation and the myeloproliferative disorders

Hematological Oncology, 2005
AbstractThe discovery this year of a single mutation in the Janus Kinase (JAK)‐2 gene in a high percentage of cases of polycythaemia vera (PV), essential thrombocythaemia (ET) and myelofibrosis suggests that it maybe the underlying molecular mechanism for these disorders.
Percy, M.J., McMullin, Mary
openaire   +3 more sources

Absence of JAK2 V617F mutation in thalassemia intermedia patients

Molecular Biology Reports, 2008
JAK2 is a cytoplasmic tyrosine kinase that has a vital role in signal transduction from several hemopoietic growth factor receptors. The JAK2 V617F mutation has been implicated in a variety of diseases mainly related to myeloproliferative disorders including polycythemia Vera, essential thrombocythemia, and idiopathic Myelofibrosis but has not been ...
Ali Taher, Rami Mahfouz, Zaher K Otrock
exaly   +3 more sources

The JAK2 ^V617F mutation and thrombosis

British Journal of Haematology, 2008
Summary Since the discovery of the JAK2 V617F mutation, the clinical and pathological consequences of this acquired defect have been extensively investigated to determine whether its presence characterises a distinct subgroup of myeloproliferative ...
S K, Austin, J R, Lambert
openaire   +2 more sources

JAK2 V617F Mutation in Essential Thrombocythemia.

Blood, 2006
Abstract Background: Essential thrombocythemia (ET) is thought to reflect transformation of a multipotent hematopoietic stem cell, but its molecular pathogenesis has remained obscure. But tyrosine kinase, especially Janus kinase 2 (JAK2) has been implicated in myeloproliferative disorders other than chronic myeloid leukemia.
Soo-Mee Bang, Soo-Jin Yoo, Jae-Hoon Lee, Dong-Bok Shin, Yiel Hea Seo, Pil Whan Park, Jeong Yeal Ahn   +6 more
openaire   +1 more source

Evaluation of the JAK2 V617F gene mutation in myeloproliferative neoplasms cases: a one-center study from Eastern Anatolia

Biyokimya Dergisi, 2019
Objective: Detection of JAK2 V617F in myeloproliferative neoplasms (MPNs) is very important in both diagnosis and disease progression. In our study, we investigated the frequency of JAK2 V617F mutation in patients with myeloproliferative disorders ...
Gonca Gülbay, Irfan Kuku, Emin Kaya
exaly   +2 more sources

JAK2 V617F mutation is absent in chronic lymphocytic leukemia

Leukemia & Lymphoma, 2006
The expansion of leukemic clone in B-chronic lymphocytic leukemia (CLL) has been related to signals from the micro-environment that influence the balance between anti-apoptotic and pro-apoptotic si...
Stéphanie, Poulain, Maud, Merchez, Agnès, Daudignon, Marc, Simon, Patrick, Duthilleul, Pierre, Morel   +5 more
openaire   +2 more sources

Is the JAK2 V617F Mutation a Hallmark for Different Forms of Thrombosis?

Acta Haematologica, 2010
<i>Background/Aims:</i> The association between venous thrombosis outside the splanchnic area as well arterial thromboembolism and the JAK2 V617F mutation, an important marker for chronic myeloproliferative neoplasms (MPN), is not completely clear.
Katja, Zerjavic, Boris, Zagradisnik, Spela, Stangler Herodez, Lidija, Lokar, Marjana, Glaser Krasevac, Nadja, Kokalj Vokac   +5 more
openaire   +2 more sources